[Scrotal testosterone patches: a good addition to therapeutic options for hypogonadal men].
OBJECTIVE
To report the experience with treatment of hypogonadal men with the scrotal application of testosterone patches.


METHODS
Prospective and descriptive.


METHODS
In 12 unselected hypogonadal men (aged 27-58 years; serum concentration of testosterone < 10 nmol/l) who complained of adverse effects of oral androgen treatment, the treatment was changed to scrotal application of testosterone patches (Testoderm). First the androgen substitution was stopped for 6 weeks. Follow-up was 4-5 years, during which regular laboratory tests were carried out, the patients filling in questionnaires regarding their general mood and the frequency of sexual feelings/activities.


RESULTS
Testosterone levels reached physiological values and a beneficial effect was observed on general mood and sexual functioning. These effects remained stable throughout the entire period of 4-5 years of study. Skin reactions occurred in 2 men. Dihydrotestosterone levels increased to supraphysiological values. Other clinical, biochemical and haematological parameters did not reveal any detrimental effects. The patch, which should be applied to a dry and shaved scrotal skin, was a satisfying androgen replacement therapy for more than 4 years in 7 out of 12 men.


CONCLUSIONS
In this open study in hypogonadal men with complaints about previous testosterone therapy, scrotal testosterone patches were a useful therapy, leading to the testosterone levels in the physiological range.
Asscheman
H
H
Academisch Ziekenhuis Vrije Universiteit, afd. Endocrinologie, Amsterdam.
Gooren
L J
LJ
D000279:Administration, Cutaneous; D000328:Adult; D013196:Dihydrotestosterone / Q000097:blood; D005500:Follow-Up Studies; D020249:Hormone Replacement Therapy / Q000379:methods*; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D007989:Libido; D008297:Male; D008875:Middle Aged; D010352:Patient Dropouts; D012611:Scrotum / Q000187:drug effects*; D012723:Sex; D013739:Testosterone / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D016896:Treatment Outcome
D013196:Dihydrotestosterone; D013739:Testosterone